PRZOOM - /newswire/ -
Winston-Salem, NC, United States, 2012/05/30 - Stocks to watch Wednesday include Medical Marijuana (Pinksheets: MJNA) $0.054 and Osiris Therapeutics (Nasdaq: OSIR) $6.49 - SmallCapReview.com.
The Board of Directors of Medical Marijuana (Pinksheets: MJNA) $0.054, is proud to announce today that it has elected Vincent "Tripp" Keber III to serve on the Board of Directors of the Company, effective immediately.
Mr. Keber previously accepted the position of President and CEO of the Company subsidiary Red Dice Holdings, LLC and is responsible for the overall strategy, licensing, branding and expansion efforts related to the various medical marijuana and hemp related portfolio companies associated with MJNA. In addition, Mr. Keber is President of the Manufacturing and Non-Pharmaceutical Division of the Company charged with overseeing research and development, sales and marketing of hemp related products both domestically and internationally. He also holds the position of Managing Director for Dixie Elixirs & Edibles LLC, which is recognized by the State of Colorado Medical Marijuana Enforcement Division as a medical marijuana infused products manufacturer.
Mr. Keber is a Founding Member and current Board Director of the National Cannabis Industry Association and also serves on the Advisory Board of the Colorado Medical Marijuana Industry Group.
What They Do: Medical Marijuana's mission is to be the premier cannabis and hemp industry innovators, leveraging its team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit.
Osiris Therapeutics (Nasdaq: OSIR) $6.49. Announced Tuesday after market close that it has received transitional pass-through status from the Center for Medicare & Medicaid Services (“CMS”), with C-Codes being designated for Grafix®. Further, the product has been assigned pass-through status under Medicare's outpatient prospective payment system (“OPPS”), effective July 1, 2012. These codes will assist in facilitating reimbursement when Grafix products are used to treat Medicare patients with acute and chronic wounds in the hospital outpatient department and ambulatory surgical center settings.
“We are very pleased with CMS, and their decision to assign pass-through codes for our Grafix line of Biosurgery products,” said Frank Czworka, Executive Director, Wound Care of Osiris Therapeutics. “This step will allow more Medicare patients and their providers to have greater access to these next-generation regenerative medicine products."
What They Do: Osiris Therapeutics, Inc. is the leading stem cell company, having developed the world’s first approved stem cell drug, Prochymal.
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has been compensated three thousand five hundred dollars by a third party SmallCapVoice for its services with regards to Medical Marijuana.